In-house or Outsource? Considerations for Biotechs at Drug Manufacturing Decision Crossroads by Joseph Fetterman | 11 March 2020
A “Spark of Opportunity” Emerges in Colliers' Philadelphia New Life Sciences Report by Joseph Fetterman | 14 May 2019
